Physician profile
Anas Nahhas
NPI 1780648873
$9,456.79
in general payments reported to CMS, 2019-2025
28 companies · $3,782 in 2025
The $3,782 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $85.70 · 2021: $199 · 2022: $735 · 2023: $1,501 · 2024: $2,597 · 2025: $3,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,044 · Consulting Fee: $1,581 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,044.25 |
| Consulting Fee | $1,581.00 |
| Education | $254.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,941.62 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,833.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,713.21 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Electromed, INC. | $717.08 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $515.72 | 2019-2025 | Xywav |
| Grifols USA, LLC | $508.59 | 2020-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.04 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $271.95 | 2020-2025 | Dupixent |
| Insmed, INC. | $271.66 | 2023-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $268.89 | 2022-2024 | Glassia, Cuvitru |
| Genentech USA, INC. | $142.73 | 2019-2022 | |
| Inspire Medical Systems, INC. | $139.07 | 2025 | Inspire |
| Amgen INC. | $138.33 | 2023-2024 | Tezspire |
| Merck Sharp & Dohme LLC | $107.07 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Inogen, INC. | $85.12 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.17 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $66.21 | 2021-2022 | |
| Philips North America LLC | $56.53 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Lilly USA, LLC | $52.17 | 2025 | Zepbound |
| Mylan Specialty L.P. | $40.02 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $28.14 | 2025 | Purified Cortrophin Gel |
| Advanced Respiratory, INC | $25.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.80 | 2022 | |
| United Therapeutics Corporation | $21.06 | 2021 | |
| Baxter Healthcare | $15.43 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $15.21 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $13.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Nahhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.